5 Conclusion
In spite of limitations of this chapter, which do not cover all aspects or fields in
which clinical pharmacology is directly involved in the individualization of the
therapy, it could be concluded that contribution of this clinical discipline for
personalization of therapy is exceptionally large. It is also important to emphasize
that personalized medicine will probably lose, in the future, this adjective “person-
alized” since it is a unique medicine that uses all the tools we have at disposal in
order to use drugs optimally for individual patients. In this approach, clinical
pharmacologists certainly have a particularly important place.
References
Alfirevic A, Pirmohamed M (2012) Predictive genetic testing for drug-induced liver injury:
considerations of clinical utility. Clin Pharmacol Ther 92(3):376–380. doi:10.1038/clpt.2012.
107
Aronson JK (2010) A manifesto for clinical pharmacology from principles to practice. Br J Clin
Pharmacol 70:3–13
Bates S (2010) Progress towards personalized medicine. Drug Discov Today 15:115–120
Burton ME, Shaw LM, Shentag JJ, Evans WE (2006) Applied pharmacokinetics & pharmacody-
namics, 4th edn. Lippincott Williams & Wilkins, Baltimore, Philadelphia
Cascorbi I, Tyndale R (2014) Progress in pharmacogenomics: bridging the gap from research to
practice. Clin Pharmacol Ther 95(3):231–235. doi:10.1038/clpt.2013.235
Caudle KE, Klein TE, Hoffman JM et al (2014) Incorporation of pharmacogenomics into routine
clinical practice: the clinical pharmacogenetics implementation consortium (CPIC) guideline
development process. Curr Drug Metab 15(2):209–217
Dourakis SP (2008) Drug therapy in liver diseases. Ann Gastroenterol 21(4):215–217
Eadie MJ (1995) The role of therapeutic drug monitoring in improving the cost effectiveness of
anticonvulsant therapy. Clin Pharmacokinet 29:29–35
Eadie MJ (1997) Indications for plasma drug monitoring in patients with epilepsy.
Pharmacoeconomics 11:343–349
Ghiculescu RA (2008) Therapeutic drug monitoring: which drugs, why, when and how to do it?
Aust Prescr 31:42–44
Gross AS (2001) Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 52(Suppl
1):5–10
Hartmann B, Czock D, Keller K (2010) Drug therapy in patients with chronic renal failure. Dtsch
Arztebl Int 107(37):647–656
IATDMCT Executive Committee (2011) Definition of TDM&CT.http://www.iatdmct.org/about-
us/about-association/about-definitions-tdm-ct.html. Accessed 12 Apr 2014
Johansson I, Ingelman-Sundberg M (2011) Genetic polymorphism and toxicology- with emphasis
on cytochrome p450. Toxicol Sci 120(1):1–13. doi:10.1093/toxsci/kfq374
Kaniwa N, Saito Y (2013) Pharmacogenomics of severe cutaneous adverse reactions and drug-
induced liver injury. J Hum Genet 58(6):317–326. doi:10.1038/jhg.2013.37
Marshall WJ, Bangert SK (2008) Clinical chemistry, 6th edn. Mosby Elsevier, Edinburgh, London
Matzke GR, Aronoff GR, Atkinson AJ, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe
DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA,
Inker LA, Umans JG, Murray P (2011) Drug dosing consideration in patients with acute and
Personalized Medicine in Clinical Pharmacology 277